Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver size may hold key to immunotherapy response

NCT ID NCT07782632

Knowledge-focused Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study looks at whether measuring the liver's functional and total volume before treatment can help predict how well patients with advanced liver cancer respond to immunotherapy. Researchers will review imaging and clinical data from 467 patients who received immunotherapy for unresectable hepatocellular carcinoma. The goal is to see if these simple measurements could guide treatment decisions and improve survival predictions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Baseline liver volume volumetric analysis (imaging-based measurement of functional and total liver volume)
What this could lead to
If liver volume predicts treatment response, doctors could better tailor immunotherapy decisions for liver cancer patients.
What could go wrong
This is a retrospective observational study, so it can show associations but not prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 467 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with unresectable hepatocellular carcinoma (HCC) who received immunotherapy across multiple medical centers, including the First Affiliated Hospital of University of Science and Technology of China, Zhengzhou University First Affiliated Hospital, and Fuyang Second People's Hospital, who met all specified inclusion and exclusion criteria.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18 years. * Clinically or histologically confirmed unresectable hepatocellular carcinoma (HCC). * Received immunotherapy as part of their tumor treatment regimen. * Availability of high-quality baseline pre-treatment imaging data suitable for functional liver volume and total liver volume segmentation. * Complete clinical and follow-up survival data. Exclusion Criteria: * \- Prior surgical resection or liver transplantation for HCC. * Co-existence of other concurrent primary malignant tumor types. * Severe image artifacts or technical limitations that prevent robust liver volume quantification. * Incomplete medical records, missing key baseline clinical data, or loss to follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of University of Science and Technology of China

    RECRUITING

    Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.